Selected as Top 7 Start-Up Finalist in ‘Hello Tomorrow’ Global Heath Competition

LUND, Sweden — /January 10, 2019/ — SAGA Diagnostics announces today that we have been selected as a Worldwide Top 7 Finalist in the Global Health category, Hello Tomorrow Start-Up Competition!  Out of more than 4,500 companies from over 100 countries screened, we were selected by a prestigious industry panel and will present our ultrasensitive cancer monitoring company and have a chance to win at the Global Summit in Paris on March 14-15, 2019 (http://hello-tomorrow.org/summit).

“It feels great for the entire SAGA team to be honored with this accolade,” says CEO Lao Saal.


Contact: CEO Lao Saal, M.D. Ph.D.   lao.saal@sagadiagnostics.com   Phone: +46 (0)70 – 888 52 61

About SAGA Diagnostics

SAGA Diagnostics AB is a personalized cancer genomics and disease monitoring company that offers molecular genetic testing of tissue biopsies and non-invasive “liquid biopsies” such as blood samples. SAGA helps pharmaceutical companies, scientists, and healthcare providers to detect actionable mutations, stratify patient groups, and monitor treatment response more accurately and to an industry-leading lower limit of detection of 0.001%. Analysis of circulating tumor DNA using these proprietary technologies gives SAGA unique ultrasensitivity, and gives patients peace of mind.